Sepsis Clinical Trial
Official title:
A Prospective Study on the Diagnosis, Severity and Prognosis of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in Sepsis & Related Complications
Triggering receptor expressed on myeloid cells-1 is a member of the immunoglobulin
superfamily of receptors that is specifically expressed on the surfaces of monocytes and
neutrophils.TREM-1 expression is increased in infectious diseases and is associated with the
release of soluble TREM-1 (sTREM-1).There has been demonstrated that the value of plasma
sTREM-1 levels as an indicator of sepsis was superior, although other studies reported that
the value of sTREM-1 for diagnosing sepsis was inferior.An increasing number of studies
indicate that there are increased levels of sTREM-1 in body fluid samples for the following
diseases and conditions: sepsis, pneumonia, pleural effusion, septic arthritis, meningitis,
peritonitis, and uterine cavity infection.
Inflammation is now believed to play a major role in the pathophysiology of AKI. It is
hypothesized that the initial insult results in morphological and/or functional changes in
vascular endothelial cells and/or in tubular epithelium in sepsis models. Then, leukocytes
including neutrophils, macrophages, natural killer cells, and lymphocytes infiltrate into
the injured kidneys and induce the generation of inflammatory mediators. Whether urine
sTREM-1 could also be detected and its significance in sepsis and AKI has not been reported
yet.
The present study focused on the value of serum & urine sTREM-1 for sepsis identification,
severity and prognosis assessments, and potential sepsis-related AKI. We also made
comparisons between sTREM-1 and WBC counts, serum CRP, serum PCT, urine output,CC SCr, and
BUN among sepsis patients.
n/a
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |